Walleye Capital’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Buy
+18,425
New +$991K ﹤0.01% 2056
2025
Q4
Sell
-56,422
Closed -$1.73M 4524
2025
Q3
$1.73M Buy
+56,422
New +$1.29M 0.01% 1685
2024
Q4
Sell
-163,997
Closed -$5.49M 4801
2024
Q3
$5.49M Buy
+163,997
New +$5.6M 0.01% 1111
2024
Q2
Sell
-9,015
Closed -$203K 5551
2024
Q1
$203K Buy
+9,015
New +$213K ﹤0.01% 3965
2023
Q2
Sell
-10,235
Closed -$223K 4275
2023
Q1
$223K Sell
10,235
-1,144
-10% -$27.8K ﹤0.01% 2391
2022
Q4
$353K Buy
+11,379
New +$321K 0.01% 1679
2022
Q1
Sell
-77,784
Closed -$2.7M 2269
2021
Q4
$2.7M Buy
+77,784
New +$2.47M 0.08% 260
2020
Q4
Sell
-20,934
Closed -$309K 925
2020
Q3
$309K Buy
+20,934
New +$378K 0.03% 503
2020
Q2
Sell
-10,648
Closed -$151K 605
2020
Q1
$151K Sell
10,648
-3,252
-23% -$49.3K 0.03% 503
2019
Q4
$226K Buy
+13,900
New +$329K 0.01% 1049
2019
Q3
Sell
-4,790
Closed -$270K 1866
2019
Q2
$270K Buy
+4,790
New +$345K 0.03% 787

Other funds holding ANAB

Walleye Capital's ANAB Position: Q1 2026 in Review

Walleye Capital opened a new position in AnaptysBio (ANAB) in Q1 2026: 18,425 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #2056 among its holdings. This is a return to the name: Walleye Capital previously reported a position in ANAB as recently as Q3 2025.

Walleye Capital first reported a position in ANAB in Q2 2019 and has held it in 11 quarters since. The position peaked at $5.49M in Q3 2024. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Walleye Capital held 18,425 shares of AnaptysBio worth $1.02M as of Q1 2026.
  • AnaptysBio was a new Walleye Capital position in Q1 2026.
  • AnaptysBio made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2056 holding.
  • Walleye Capital first reported a position in AnaptysBio in Q2 2019 and has held it in 11 quarters since.
  • Walleye Capital's AnaptysBio position peaked at $5.49M in Q3 2024.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.